Monopar Therapeutics (MNPR) Research & Development (2017 - 2026)
Monopar Therapeutics (MNPR) posted Research & Development of $2.6 million for Q3 2025, up 49.7% sequentially from $1.7 million in Q2 2025, and up 163.11% YoY from $984278.0 in Q3 2024.
Monopar Therapeutics (MNPR) Research & Development (2017 - 2026) Analysis & Trends
Monopar Therapeutics has reported Research & Development for 9 years, with the latest figure at $2.6 million in Q3 2025.
- Quarterly Research & Development rose 163.11% year-over-year to $2.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $7.5 million (up 70.12% YoY) and the FY2024 annual result came in at $4.6 million, changed N/A from the prior year.
- Research & Development grew to $2.6 million in Q3 2025 per MNPR's latest filing, from $1.7 million in the prior quarter.
- Over five years, Research & Development peaked at $2.6 million in Q3 2025 and troughed at $966110.0 in Q1 2024.
- A 5-year average of $1.6 million and a median of $1.6 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2021 and 2024: Research & Development soared 250.39% in 2021, then sank 41.57% in 2024.
- Over 5 years, Research & Development stood at $2.0 million in 2021, then rose by 6.07% to $2.1 million in 2022, then sank by 37.4% to $1.3 million in 2023, then rose by 15.35% to $1.5 million in 2024, then jumped by 70.53% to $2.6 million in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $2.6 million, $1.7 million, and $1.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | 4.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.77 Mn |
| Sep 30, 2025 | 2.59 Mn |
| Jun 30, 2025 | 1.73 Mn |
| Mar 31, 2025 | 1.64 Mn |
| Dec 31, 2024 | 1.52 Mn |
| Sep 30, 2024 | 984,278.00 |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 966,110.00 |
| Sep 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 1.59 Mn |
| Mar 31, 2023 | 1.65 Mn |
| Dec 31, 2022 | 2.10 Mn |
| Sep 30, 2022 | 1.73 Mn |
| Jun 30, 2022 | 2.08 Mn |
| Mar 31, 2022 | 1.68 Mn |
| Dec 31, 2021 | 1.98 Mn |
| Sep 30, 2021 | 1.83 Mn |
| Jun 30, 2021 | 1.48 Mn |
| Mar 31, 2021 | 1.21 Mn |
| Dec 31, 2020 | 1.63 Mn |